April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
Half-dose versus half-fluence photodynamic therapy for chronic central serous chorioretinopathy
Author Affiliations & Notes
  • Ryo Matoba
    Okayama university, Okayama, Japan
  • Yusuke Shiode
    Okayama university, Okayama, Japan
  • Tetsuhiro Kawata
    Okayama university, Okayama, Japan
  • Mio Hosokawa
    Okayama university, Okayama, Japan
  • Shuhei Kimura
    Okayama university, Okayama, Japan
  • Yuki Morizane
    Okayama university, Okayama, Japan
  • Fumio Shiraga
    Okayama university, Okayama, Japan
  • Footnotes
    Commercial Relationships Ryo Matoba, None; Yusuke Shiode, None; Tetsuhiro Kawata, None; Mio Hosokawa, None; Shuhei Kimura, None; Yuki Morizane, None; Fumio Shiraga, Alcon Japan (C), Bausch & Lomb Japan (C), Byer (C), Novartis Pharma (C), Santen Pharma (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 6376. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ryo Matoba, Yusuke Shiode, Tetsuhiro Kawata, Mio Hosokawa, Shuhei Kimura, Yuki Morizane, Fumio Shiraga; Half-dose versus half-fluence photodynamic therapy for chronic central serous chorioretinopathy. Invest. Ophthalmol. Vis. Sci. 2014;55(13):6376.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To compare the efficacy and safety of half-dose verteporfin photodynamic therapy (PDT) and half-fluence PDT in patients with chronic central serous chorioretinopathy (CSC).

Methods: The records of 41 eyes of 39 CSC patients treated with PDT between January 2010 and August 2013 were retrospectively reviewed. Thirty eyes (28 patients) received PDT with half-dose (3mg/m2) verteporfin. Eleven eyes (11 patients) received PDT with half-fluence (25J/cm2). All patients were followed up at least 3 months. Outcome measures included the best correct visual acuity (BCVA), the central retinal thickness (CRT) and the proportion of eyes with complete resolution of serous retinal detachment (SRD) in the macula.

Results: At baseline, the mean BCVA and CRT of both groups did not differ significantly. At 3 months after treatment, BCVA (logMAR) of both groups improved significantly; from 0.27 to 0.13 (p < 0.05) and 0.20 to 0.09 (p < 0.05) in the half dose PDT group and the half-fluence PDT group, respectively. There was no difference in BCVA at 3 months between the 2 groups (p = 0.711). At 3 months, the CRT of both groups decreased significantly, and the CRT in the half-fluence PDT group was significantly thinner than that the half-dose PDT group (158.7 ± 36.4µm vs. 128.5 ± 28.3µm; p = 0.01). The complete resolution of SRD was achieved in 27 eyes (90%) in the half-dose PDT group and 10 eyes (91%) in the half-fluence PDT group. We did not observe any recurrences, secondary choroidal neovascularization and systemic side effects throughout the follow up period.

Conclusions: Both half-dose and half-fluence PDTs showed significant efficacy for chronic CSC. Half-dose PDT may less likely to cause the retinal atrophy than half-fluence PDT.

Keywords: 647 photodynamic therapy • 585 macula/fovea • 462 clinical (human) or epidemiologic studies: outcomes/complications  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.